Back
Sarepta Therapeutics Vs. Innodata Industry Stock Comparison
Sell
50
SRPT
Sarepta Therapeutics
Last Price:
$128.18
Seasonality Move:
9.24%
Buy
63
INOD
Innodata
Last Price:
$43.93
Seasonality Move:
3.52%
Sell
50
Sarepta Therapeutics (SRPT)
is a Sell
Is Sarepta Therapeutics a Buy, Sell or Hold?
-
The current Sarepta Therapeutics [SRPT] share price is $126.29. The Score for SRPT is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.
-
SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
-
This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $126.29Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing slight buying pressure.
SRPT Technical Analysis
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | 0.12 | Buy |
Relative Strength Index (14 RSI): | 56.51 | Buy |
Chaikin Money Flow: | 109207 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (120.86 - 129.32) | Buy |
Bollinger Bands (100): | (117.93 - 133.51) | Buy |
INOD Technical Analysis
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | 1.48 | Buy |
Relative Strength Index (14 RSI): | 57.39 | Buy |
Chaikin Money Flow: | 1235602 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (37.31 - 44.33) | Buy |
Bollinger Bands (100): | (14.45 - 38.63) | Buy |
SRPT Moving Averages
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 122.57 | Buy |
20-day SMA: | 123.78 | Buy |
50-day SMA: | 122.52 | Buy |
200-day SMA: | 129.64 | Sell |
8-day EMA: | 123.22 | Buy |
20-day EMA: | 123.01 | Buy |
50-day EMA: | 123.43 | Buy |
200-day EMA: | 125.73 | Buy |
INOD Moving Averages
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 42.92 | Buy |
20-day SMA: | 40.73 | Buy |
50-day SMA: | 36.64 | Buy |
200-day SMA: | 19.33 | Buy |
8-day EMA: | 42 | Buy |
20-day EMA: | 40.96 | Buy |
50-day EMA: | 36.31 | Buy |
200-day EMA: | 22.92 | Buy |
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
-
Analysts estimate an earnings increase this quarter of $2.79 per share, a decrease next quarter of $0.00 per share, an increase this year of $7.84 per share, and an increase next year of $4.82 per share.
Innodata Earnings Growth & INOD Earnings Dates
-
Analysts estimate an earnings decrease this quarter of $0.02 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.04 per share, and an increase next year of $0.41 per share.
Sarepta Therapeutics Technical Analysis
Dec 19 | Dec 20 | Dec 23 | Dec 24 | Dec 26 | Dec 27 | Dec 30 | Dec 31 | Jan 2 | Jan 3 | |
---|---|---|---|---|---|---|---|---|---|---|
Dec | Jan | |||||||||
19 | 20 | 23 | 24 | 26 | 27 | 30 | 31 | 02 | 03 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Innodata Technical Analysis
Dec 19 | Dec 20 | Dec 23 | Dec 24 | Dec 26 | Dec 27 | Dec 30 | Dec 31 | Jan 2 | Jan 3 | |
---|---|---|---|---|---|---|---|---|---|---|
Dec | Jan | |||||||||
19 | 20 | 23 | 24 | 26 | 27 | 30 | 31 | 02 | 03 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |